ASMB (Assembly Biosciences) Gross-Profit-to-Asset % : 25.40% (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Assembly Biosciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Assembly Biosciences's annualized Gross Profit for the quarter that ended in Sep. 2024 was $27.38 Mil. Assembly Biosciences's average Total Assets over the quarter that ended in Sep. 2024 was $107.79 Mil. Therefore, Assembly Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 25.40%.

Assembly Biosciences Gross-Profit-to-Asset % Historical Data

The historical data trend for Assembly Biosciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Gross-Profit-to-Asset % Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

5.25

25.39

2.64

6.00

Assembly Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	30.41	18.03	29.02	25.40

Competitive Comparison of Assembly Biosciences's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Assembly Biosciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Gross-Profit-to-Asset % falls into.

Assembly Biosciences Gross-Profit-to-Asset % Calculation

Assembly Biosciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	7.163	/	( (101.794	+	136.823)	/ 2 )
	=	7.163	/	119.3085
	=	6.00 %

Assembly Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	27.38	/	( (115.323	+	100.262)	/ 2 )
	=	27.38	/	107.7925
	=	25.40 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Assembly Biosciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Assembly Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (NAS:ASMB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

V7B:Germany

Address

Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Executives

Alexander Schornstein	10 percent owner	KAISER-FRIEDRICH-ALLEE 2, AACHEN 2M 52074
Nicole S White	officer: Chief Manufacturing Officer	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Jason A Okazaki	officer: Chief Legal & Business Officer	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Jeanette M Bjorkquist	officer: Principal Accounting Officer	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
John G Mchutchison	director, officer: CEO and President	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Delaney William E Iv	officer: CSO, Virology	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Michael P. Samar	officer: See Remarks	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Luisa M Stamm	officer: Chief Medical Officer	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST, SUITE 310, CARMEL IN 46032
Michael Houghton	director	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Lisa Johnson-pratt	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Jacqueline Sybil Papkoff	officer: See remarks	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN STREET, SUITE 310, CARMEL IN 46032
Gina Consylman	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Richard James Colonno	officer: Chief Science Officer	ASSEMBLY BIOSCIENCES, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Thomas Joseph Russo	officer: CFO	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032